

Erez Bar-Haim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9929013/publications.pdf>

Version: 2024-02-01

54
papers

1,345
citations

361413

20
h-index

361022

35
g-index

64
all docs

64
docs citations

64
times ranked

1528
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience. <i>Journal of Infectious Diseases</i> , 2022, 225, 785-792.	4.0	38
2	Preliminary nonclinical safety and immunogenicity of an rVSV- $\hat{\Gamma}$ G-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs. <i>Archives of Toxicology</i> , 2022, 96, 859-875.	4.2	8
3	T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern. <i>Viruses</i> , 2022, 14, 347.	3.3	12
4	Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice. <i>Vaccines</i> , 2022, 10, 613.	4.4	2
5	Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. <i>Frontiers in Immunology</i> , 2022, 13, 868915.	4.8	32
6	Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients – A Prospective Study. <i>Transplant International</i> , 2022, 35, 10204.	1.6	25
7	Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults \geq 60 Years. <i>Journal of Clinical Medicine</i> , 2022, 11, 2649.	2.4	8
8	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. <i>ACS Nano</i> , 2021, 15, 9627-9637.	14.6	66
9	Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. <i>Nano Letters</i> , 2021, 21, 4774-4779.	9.1	20
10	Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. <i>Cell Reports</i> , 2021, 35, 109305.	6.4	38
11	Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection. <i>Pathogens</i> , 2021, 10, 940.	2.8	1
12	Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity. <i>Nature Communications</i> , 2021, 12, 5819.	12.8	40
13	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study). <i>BMJ Open</i> , 2021, 11, e055611.	1.9	22
14	Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 638-638.	1.4	3
15	Early Diagnosis of Pathogen Infection by Cell-Based Activation Immunoassay. <i>Cells</i> , 2019, 8, 952.	4.1	8
16	Draft Genome Sequence of a Rare Israeli Clinical Isolate of <i>Burkholderia pseudomallei</i> . <i>Microbiology Resource Announcements</i> , 2019, 8, .	0.6	1
17	Case Report: Imported Melioidosis from Goa, India to Israel, 2018. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 580-584.	1.4	4
18	Neonatal mice possess two phenotypically and functionally distinct lung-migratory CD103+ dendritic cell populations following respiratory infection. <i>Mucosal Immunology</i> , 2018, 11, 186-198.	6.0	40

#	ARTICLE	IF	CITATIONS
19	Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus. <i>Frontiers in Immunology</i> , 2018, 9, 1861.	4.8	31
20	Novel CTL epitopes identified through a <i>Y. pestis</i> proteome-wide analysis in the search for vaccine candidates against plague. <i>Vaccine</i> , 2017, 35, 5995-6006.	3.8	10
21	A novel live attenuated anthrax spore vaccine based on an acapsular <i>Bacillus anthracis</i> Sterne strain with mutations in the <i>htrA</i> , <i>lef</i> and <i>cya</i> genes. <i>Vaccine</i> , 2017, 35, 6030-6040.	3.8	21
22	Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung. <i>Vaccine</i> , 2017, 35, 7001-7009.	3.8	4
23	A Simple Luminescent Adenylate-Cyclase Functional Assay for Evaluation of <i>Bacillus anthracis</i> Edema Factor Activity. <i>Toxins</i> , 2016, 8, 243.	3.4	7
24	Next-Generation <i>Bacillus anthracis</i> Live Attenuated Spore Vaccine Based on the <i>htrA</i> - (High) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 T	3.3	18
25	Toxins as biological weapons for terrorâ€™ characteristics, challenges and medical countermeasures: a mini-review. <i>Disaster and Military Medicine</i> , 2016, 2, 7.	1.0	32
26	Protective Immunity against Lethal <i>F. tularensis</i> holarctica LVS Provided by Vaccination with Selected Novel CD8+ T Cell Epitopes. <i>PLoS ONE</i> , 2014, 9, e85215.	2.5	11
27	CD8+ TCR Transgenic Strains Expressing Public versus Private TCR Targeting the Respiratory Syncytial Virus KdM282â€™90 Epitope Demonstrate Similar Functional Profiles. <i>PLoS ONE</i> , 2014, 9, e99249.	2.5	7
28	YopP-Expressing Variant of <i>Y. pestis</i> Activates a Potent Innate Immune Response Affording Cross-Protection against Yersiniosis and Tularemia. <i>PLoS ONE</i> , 2013, 8, e83560.	2.5	7
29	Consequences of Delayed Ciprofloxacin and Doxycycline Treatment Regimens against <i>Francisella tularensis</i> Airway Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5406-5408.	3.2	14
30	Whole-Genome Immunoinformatic Analysis of <i>F. tularensis</i> : Predicted CTL Epitopes Clustered in Hotspots Are Prone to Elicit a T-Cell Response. <i>PLoS ONE</i> , 2011, 6, e20050.	2.5	15
31	The Involvement of IL-17A in the Murine Response to Sub-Lethal Inhalational Infection with <i>Francisella tularensis</i> . <i>PLoS ONE</i> , 2010, 5, e11176.	2.5	41
32	Effect of Disruption of <i>mglA</i> on the Virulence and Immunogenicity of the <i>Francisella tularensis</i> Live Vaccine Strain (LVS). , 2010, , 219-227.		1
33	The Inverse Relationship Between Cytotoxicity of <i>Y. pestis</i> and Its Virulence. , 2010, , 45-55.		0
34	The Interactions Between Pathogens and Dendritic Cells: From Paralysis of Cells to Their Recruitment for Bacterial Colonization. , 2010, , 89-98.		0
35	Consequences of Antibiotic Treatment of <i>Francisella tularensis</i> Airways Infections. , 2010, , 207-212.		0
36	<i>Yersinia pestis</i> Endowed with Increased Cytotoxicity Is Avirulent in a Bubonic Plague Model and Induces Rapid Protection against Pneumonic Plague. <i>PLoS ONE</i> , 2009, 4, e5938.	2.5	39

#	ARTICLE	IF	CITATIONS
37	Interrelationship between Dendritic Cell Trafficking and Francisella tularensis Dissemination following Airway Infection. PLoS Pathogens, 2008, 4, e1000211.	4.7	63
38	â€˜1-8 interferon inducible gene familyâ€™: putative colon carcinoma-associated antigens. British Journal of Cancer, 2007, 97, 1655-1663.	6.4	10
39	Discordance in the Effects of Yersinia pestis on the Dendritic Cell Functions Manifested by Induction of Maturation and Paralysis of Migration. Infection and Immunity, 2006, 74, 6365-6376.	2.2	39
40	Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity. Clinical Cancer Research, 2005, 11, 4955-4961.	7.0	103
41	Efficacious, nontoxicogenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine, 2005, 23, 5688-5697.	3.8	30
42	In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Therapy, 2004, 11, 237-248.	4.6	22
43	MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. British Journal of Cancer, 2004, 91, 398-407.	6.4	20
44	Expression of FasL by tumor cells does not abrogate anti-tumor CTL function. Immunology Letters, 2004, 91, 119-126.	2.5	5
45	Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8+ T cell population in different tissues. Vaccine, 2004, 22, 1390-1394.	3.8	14
46	CD66a Interactions Between Human Melanoma and NK Cells: A Novel Class I MHC-Independent Inhibitory Mechanism of Cytotoxicity. Journal of Immunology, 2002, 168, 2803-2810.	0.8	163
47	Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/Db-Î²2mtransgenic mice. Journal of Clinical Investigation, 2002, 110, 453-462.	8.2	30
48	Second neoplasms in patients with Merkel cell carcinoma. Cancer, 2001, 91, 1358-1362.	4.1	99
49	Anti-Tumor Vaccination in Heterozygous Congenic F1 Mice: Presentation of Tumor-Associated Antigen by the Two Parental Class I Alleles. Journal of Immunotherapy, 2000, 23, 344-352.	2.4	0
50	Antitumor vaccination using peptide based vaccines. Immunology Letters, 2000, 74, 27-34.	2.5	22
51	Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunology Letters, 1999, 70, 21-28.	2.5	12
52	MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. European Journal of Immunology, 1999, 29, 3295-3301.	2.9	79
53	Tumor-Associated Antigen Peptides as Anti-Metastatic Vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	0
54	Tumor-associated antigen peptides as anti-metastatic vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	0